Biography: Alex Gifford, MD
Certifications & Memberships
- Critical Care Medicine - American Board of Internal Medicine
- Pulmonary Disease - American Board of Internal Medicine
Fellowship | Pulmonary/Critical Care
Pulmonary/Critical Care - Dartmouth-Hitchcock Medical Center (2007 - 2010)
Residency | Internal Medicine/Chief Resident
Internal Medicine/Chief Resident - Dartmouth-Hitchcock Medical Center (2006 - 2007)
Residency | Internal Medicine
Internal Medicine - Dartmouth-Hitchcock Medical Center (2003 - 2006)
Pennsylvania State University College Of Medicine (2003)
Allegheny College (1999)
Alex H. Gifford, MD, FCCP, is Director of the Adult Cystic Fibrosis Program at University Hospitals. Dr. Gifford also serves as Director of the Cystic Fibrosis Therapeutics Development Center in the Leroy W. Matthews Cystic Fibrosis Center at University Hospitals Rainbow Babies & Children’s Hospital. Additionally, he is an associate professor of medicine at Case Western Reserve University.
Dr. Gifford graduated from the Pennsylvania State University College of Medicine in 2003. He completed his internship and residency in Internal Medicine at Dartmouth-Hitchcock Medical Center in Lebanon, New Hampshire in 2006 and served as chief medical resident in 2007. Dr. Gifford then completed his fellowship in Pulmonary and Critical Care Medicine, also at Dartmouth-Hitchcock Medical Center, in 2010. He joined the faculty of Dartmouth-Hitchcock Medical Center that year and attained the rank of Associate Professor of Medicine before coming to University Hospitals in 2021.
At Dartmouth-Hitchcock Medical Center, Dr. Gifford served as associate director of the Interstitial Lung Disease (ILD) Program. He organized a comprehensive pulmonary-rheumatology case registry that served educational and research purposes. He also contributed to a pulmonary-rheumatology interdisciplinary case conference series at which he discussed the evaluation and management of complex cases. Dr. Gifford was a local principal investigator on several phase 2 and 3 controlled trials of investigational medicinal products designed to treat idiopathic pulmonary fibrosis (IPF) and progressive-fibrotic interstitial lung disease (PF-ILD).
In addition to caring for pulmonary patients in his clinical practice, Dr. Gifford continues a clinical trials program at University Hospitals for patients with interstitial lung diseases.
University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members’ ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.
UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.
View UH’s policy (PDF) on practitioner-industry relationships.
As of December 31, 2016, Alex Gifford did not disclose any Outside Relationships with Industry.